http://www.medgenics.com/about_us.htm

Medgenics is developing a unique sustained-action therapeutic protein delivery technology for the treatment of a range of chronic diseases. The technology – called a “Biopump” – is made from the patient’s own skin and is implanted in a simple procedure to work inside the patient’s body, to produce and deliver the active protein steadily over a sustained period to treat the targeted disease. Medgenics believes that this biological approach can replace a major portion of the regular and costly injections of therapeutic proteins patients currently receive.

The Company has demonstrated proof-of-principle of its treatment procedure in a clinical trial using EPODURE in anemic patients. A long-acting version of EPODURE designed to produce and deliver a therapeutic dose of EPO steadily for six months or more began Phase I/II efficacy trials in Israel in mid-2008. Clinical trials with INFRADURE are intended follow in due course.

Beyond this, the Company plans to develop a pipeline of products based on its Biopump technology targeting the large and rapidly growing global $50+ billion protein therapy market, which is expected to grow to some $132 billion per year in 2013.

Medgenics is managed by a highly experienced team of biotechnology and biomedical device experts, and its Board of Directors and Scientific Advisory Board include highly experienced figures in the healthcare industry, in healthcare finance, as well as influential figures from the medical community and academia.

Share Price
Medgenics, Inc. commenced trading on the London Stock Exchange Alternative Investment Market (AIM), on Tuesday, 04 December 2007. The stock trades under two symbols: MEDG for Reg S shares and MEDU for unrestricted shares.

Medgenics looks to exit AIM

By Ian Lyall

March 03 2014, 8:07am
The group which is developing a the Biopump for the sustained release of therapeutic proteins.
The group which is developing a the Biopump for the sustained release of therapeutic proteins.


The biotechnology group Medgenics (NYSE MKT:MDGN, LON:MEDG) has unveiled plans to cancel its AIM listing.

The group, which is developing a Biopump for the sustained release of therapeutic proteins, said the high cost of maintaining UK quote as well as limited trading volumes were two of the reasons for the proposed London exit.

Medgenics said it will maintain its quote on the NYSE MKT (formerly the AMEX).

A vote will be heard at the stockholder’s meeting on April 8. If the proposal is approved then the last day of trading on AIM would be April 15.

Medgenics said all stock on the UK share register will be added the US register.

It said either Capita Registrars or Corporate Stock Transfer, the company's US registrar, will send out transmittal letters to all stockholders whose shares were previously UK listed “providing them with further information regarding the transfer of their shares to the company's US share register